 |
|
|
| |
Efficacy and Safety of Tobevibart (VIR-3434) Alone or in Combination With Elebsiran (VIR-2218) in Participants With Chronic Hepatitis Delta Virus Infection: Week 24 Primary Endpoint Analysis From the Phase 2 SOLSTICE Trial
|
| |
| |
AASLD 2024 Nov 15-19 San Diego
Tarik Asselah,1 Anca Streinu-Cercel,2 Alina Jucov,3 Ed Gane,4 Heiner Wedemeyer,5 Pietro Lampertico,6,7 Michael A Chattergoon,8 Sophia Chow,8 Pan Wu,8 Cara Pilowa,8 Todd Correll,8 Carey Hwang,8 Kosh Agarwal9
|
| |
|
|
|
|
|
